401 results on '"Sperling, Adam S."'
Search Results
2. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML
3. Optimizing the manufacturing and antitumour response of CAR T therapy
4. Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies
5. PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy
6. Chimeric Antigen Receptor T Cells in Multiple Myeloma
7. SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation
8. Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
9. UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability
10. The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein
11. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
12. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
13. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
14. Association of clonal hematopoiesis with chronic obstructive pulmonary disease
15. Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state
16. Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk
17. Functional dissection of inherited non-coding variation influencing multiple myeloma risk
18. Identification of Small Molecule Inhibitors of PPM1D Using a Novel Drug Discovery Platform
19. Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
20. Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
21. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
22. Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
23. Modeling and targeting of erythroleukemia by hematopoietic genome editing
24. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.
25. Identification of germline variants in adults with hemophagocytic lymphohistiocytosis
26. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
27. SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation
28. Small-molecule-induced polymerization triggers degradation of BCL6
29. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
30. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
31. Long-term persistent exposure to cigarette smoke induces AhR driven corneal endothelial dysfunction in mice
32. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
33. Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells
34. Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis
35. FIGURE 1 from Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma
36. Supplementary Table 3 from Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma
37. Supplementary Figure 3 from Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma
38. Clinical outcomes and evolution of clonal hematopoiesis in patients with newly diagnosed multiple myeloma
39. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma
40. P-099 Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma
41. Supplemental Fig. S2 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
42. Supplemental Table S6 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
43. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
44. Data from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
45. Selinexor: Targeting a novel pathway in multiple myeloma
46. Clonal Hematopoiesis in Young Women Treated for Breast Cancer
47. Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs
48. Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis
49. UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability
50. Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.